Alimera Sciences Inc ALIM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALIM is a good fit for your portfolio.
News
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders
-
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SHCR, AGR on Behalf of Shareholders
-
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SPR, AGR, AGS on Behalf of Shareholders
-
ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SHCR, BEST, VAPO on Behalf of Shareholders
-
Kuehn Law Encourages UMBF, ALIM, TBNK, and BEST Investors to Contact Law Firm
Trading Information
- Previous Close Price
- $5.59
- Day Range
- $5.56–5.60
- 52-Week Range
- $2.61–5.65
- Bid/Ask
- $5.57 / $5.59
- Market Cap
- $291.80 Mil
- Volume/Avg
- 1.3 Mil / 358,432
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.31
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 158
- Website
- https://www.alimerasciences.com
Valuation
Metric
|
ALIM
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.06 |
Price/Sales | 2.31 |
Price/Cash Flow | 56.96 |
Price/Earnings
ALIM
Financial Strength
Metric
|
ALIM
|
---|---|
Quick Ratio | 2.33 |
Current Ratio | 2.62 |
Interest Coverage | −0.74 |
Quick Ratio
ALIM
Profitability
Metric
|
ALIM
|
---|---|
Return on Assets (Normalized) | −10.05% |
Return on Equity (Normalized) | −99.02% |
Return on Invested Capital (Normalized) | −3.88% |
Return on Assets
ALIM
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Zoetis Inc Class A
ZTS
| Ysxfcvrs | Pcbm | $82.1 Bil | |||
Merck KGaA ADR
MKKGY
| Mfkdgbfp | Kvvptc | $73.2 Bil | |||
Haleon PLC ADR
HLN
| Rztbgcps | Kkrv | $41.0 Bil | |||
Viatris Inc
VTRS
| Zglcggvd | Zpsc | $14.4 Bil | |||
Dr Reddy's Laboratories Ltd ADR
RDY
| Dxpnqthqk | Bxyj | $13.7 Bil | |||
Catalent Inc
CTLT
| Nrrysfnj | Crhyf | $10.6 Bil | |||
Perrigo Co PLC
PRGO
| Vnbwfnp | Zgcy | $3.8 Bil | |||
Prestige Consumer Healthcare Inc
PBH
| Sfhwwkdmv | Mwmvww | $3.5 Bil | |||
Curaleaf Holdings Inc
CURLF
| Wkrbtkmlq | Nvm | $3.0 Bil | |||
Green Thumb Industries Inc
GTBIF
| Wwzqvgwxz | Pqtz | $2.7 Bil |